Mildrokard

General characteristics. Structure:

Active ingredient: 500 mg meldoniya.

Pharmacological properties:

Pharmacodynamics. Mildrokard is an analog of a gamma butyrobetaine, the predecessor of a carnitine.

Drug increases working capacity, reduces symptoms of a mental and physical overstrain; possesses the cardiotyre-tread and regulating system of cellular immunity action; eliminates functional disturbances somatic and the autonomic nervous system at patients - alcoholics in the period of an abstinence syndrome; it is effective in case of pathology and dystrophy of vascular system of an eyeground; carries out distribution of a volume brain blood-groove in favor of the brain ischemia centers.

Indications to use:

The lowered working capacity, physical overstrain (including at athletes); the postoperative period for rehabilitation acceleration; An ischemic heart disease (stenocardia, a myocardial infarction), chronic heart failure, a cardialgia against the background of dishormonal dystrophy of a myocardium; an abstinence alcoholic syndrome (in a combination with specific therapy); disturbances of blood supply of a brain (stroke, cerebrovascular insufficiency); an acute disorder of blood circulation in a retina, a hemophthalmia and retinal apoplexies of various etiology, fibrinferments of the central vein of a retina and its branches, retinopathies of various etiology (including diabetic and hypertensive.

Route of administration and doses:

At intellectual and physical overworks (including at athletes) the drug is administered in/in on 500 mg of 1 times a day. A course of treatment - 10-14 days. If necessary treatment is repeated in 2-3 weeks.

At unstable stenocardia and a myocardial infarction (as a part of a combination therapy) - in/in struyno, on 0.5-1 g of 1 times a day, further pass to reception of a peroral dosage form (inside, 250 mg 2 times a day the first 3-4 days then 2 times a week on 250 mg 3 times a day).

At an alcoholism (in a combination with specific therapy) - in/in on 500 mg 2 times a day. A course of treatment - 7-10 days.

At vascular pathology of an eyeground and dystrophy of a retina the drug is administered retrobulbarno and subkonjyunktivalno on 0.5 ml of 10% of solution (50 mg of Mildronate) within 10 days. At an inflammation of an eye combine with parenteral or local administration of glucocorticosteroids, at vascular dystrophic diseases - with the medicines improving microcirculation.

At disturbances of cerebral circulation: in an acute phase of cerebrovascular pathology enter in/in, 500 mg of 1 times a day within 10 days then appoint inside (in the form of peroral dosage forms), 500 mg/days. A course of treatment - 2-3 weeks.

At chronic disturbances of cerebral circulation enter 1 time, in oil on 500 mg, a day, it is desirable in the first half of day. A course of treatment - 2-3 weeks.

Features of use:

Long-term experience of treatment of an acute myocardial infarction and unstable stenocardia in cardiological departments shows that the propionate trimetilgidraziniya a dihydrate is not row drug I at an acute coronary syndrome and its use is not sharply necessary.

As drug can cause moderate tachycardia and a lowering of arterial pressure, it is necessary to be careful at a combination of a mildrokard with nitroglycerine, nifedipine, alpha adrenoblockers, antihypertensives and peripheral vazodilatator.

Side effects:

Mildrokard is usually well had at use in the recommended doses. Hypersensitivity reactions, a skin itch, dyspepsia, tachycardia, excitement, a lowering of arterial pressure are seldom possible.

Interaction with other medicines:

Strengthens effect of koronarodilatiruyushchy and some hypotensive medicines, cardiac glycosides. Mildrokard it is possible to combine with anti-anginal drugs, anticoagulants, antiagregant, antiarrhytmic medicines, diuretics, bronchial spasmolytics.

Contraindications:

Hypersensitivity, organic injury of the central nervous system, increase in intracranial pressure (at disturbance of venous outflow and intracranial tumors), pregnancy, the lactation period.

Overdose:

The overdose phenomena are not described so far.

Issue conditions:

According to the recipe

Packaging:

Solution for injections of 10% in ampoules of 5 ml in a blister strip packaging No. 10 (No. 5х2).